Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 27 people enrolled
- Started
- 1 Dec 2023
- Ended
- 17 Jun 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atomoxetine 80 mg plus Oxybutynin 5 mg
- Atomoxetine 80 MG
- Placebo
- Record updated
- 17 December 2025
Who can take part
- Age
- 21 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- diagnosed OSA (AHI≥15 events/h reported in PSG performed within one year) or Suspected OSA (snoring, sleepiness, witness apneas, other clinical symptoms)
- not using CPAP (>1 week)
Who cannot take part
- Any uncontrolled medical condition; Current use of the medications under investigation; Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid); Current use of SNRIs/SSRIs or anticholinergic medications; Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition; Respiratory disorders other than sleep disordered breathing:; chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions
- Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias
- Allergy to lidocaine
- Contraindications for atomoxetine and oxybutynin, including:; hypersensitivity to atomoxetine or oxybutynin (angioedema or urticaria); pheochromocytoma; use of monoamine oxidase inhibitors; diagnosed benign prostatic hypertrophy, urinary retention; suspected benign prostatic hypertrophy / urinary retention based on a positive answer to either of the following questions:; "During the last month, when urinating, have you had the sensation of not emptying your bladder completely more often than 1 out of 5 times?"; "During the last month, have you had a weak urinary stream more often than 1 out of 5 times?; untreated narrow angle glaucoma; bipolar disorder, mania, psychosis; history of major depressive disorder (age<24); history of attempted suicide or suicidal ideation within one year prior to screening; clinically significant constipation, gastric retention; pre-existing seizure disorders; clinically-significant kidney disorders (eGFR<60 ml/min/1.73m2); clinically-significant liver disorders; clinically-significant cardiovascular conditions; severe hypertension (SBP>180 mmHg or DBP>110 mmHg measured at baseline); cardiomyopathy (LVEF<50%) or heart failure; advanced atherosclerosis; history of cerebrovascular events; history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation; other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate; myasthenia gravis; pregnancy/breast-feeding
- Use of oral anti-coagulants
- Claustrophobia
- Pregnancy or nursing
Where in United States
- Brigham and Womens HospitalBoston, United States
About the trial
What the trial wants to find out
Current therapies available for obstructive sleep apnea (OSA) have varying degrees of efficacy due to the complex nature of the disorder. A reduction in pharyngeal muscle activity characterizes OSA, and recent research has shown that combining atomoxetine and oxybutynin improves OSA severity. Thus this may be a viable treatment option. However, the specific effects of these agents alone and in combination on pharyngeal muscle activity remain unknown. The current study will look at the impact of each drug on pharyngeal muscles to gain insight into the mechanisms of this combination.
The 3 groups in the trial
- Atomoxetine-plus-Oxybutynin (AtoOxy)Treatment being tested
80mg atomoxetine and 5mg of oxybutynin administered to participant, 30 min prior to bed.
Treatment: Atomoxetine 80 mg plus Oxybutynin 5 mg
- AtomoxetineExisting treatment, for comparison
80mg atomoxetine and placebo administered to participant, 30 min prior to bed.
Treatment: Atomoxetine 80 MG
- PlaceboPlacebo, for comparison
Placebo plus placebo administered to participant, 30mins prior to bed
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 December 2025